Cargando…

Superparamagnetic Bifunctional Bisphosphonates Nanoparticles: A Potential MRI Contrast Agent for Osteoporosis Therapy and Diagnostic

A bone targeting nanosystem is reported here which combined magnetic contrast agent for Magnetic Resonance Imaging (MRI) and a therapeutic agent (bisphosphonates) into one drug delivery system. This new targeting nanoplatform consists of superparamagnetic γFe(2)O(3) nanoparticles conjugated to 1,5-d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lalatonne, Y., Monteil, M., Jouni, H., Serfaty, J. M., Sainte-Catherine, O., Lièvre, N., Kusmia, S., Weinmann, P., Lecouvey, M., Motte, L.
Formato:	Texto
Lenguaje:	English
Publicado:	SAGE-Hindawi Access to Research 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957199/ https://www.ncbi.nlm.nih.gov/pubmed/20981332 http://dx.doi.org/10.4061/2010/747852

Ejemplares similares

Towards potential nanoparticle contrast agents: Synthesis of new functionalized PEG bisphosphonates
por: Kachbi-Khelfallah, Souad, et al.
Publicado: (2016)

New MRI contrast agents based on silicon nanotubes loaded with superparamagnetic iron oxide nanoparticles
por: Gonzalez-Rodriguez, Roberto, et al.
Publicado: (2018)

Polymer-coated superparamagnetic iron oxide nanoparticles as T(2) contrast agent for MRI and their uptake in liver
por: Ali, Lamiaa MA, et al.
Publicado: (2017)

Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents
por: Di Marco, Mariagrazia, et al.
Publicado: (2007)

Superparamagnetic Iron Oxide Nanoparticles as MRI contrast agents for Non-invasive Stem Cell Labeling and Tracking
por: Li, Li, et al.
Publicado: (2013)

Size and PEG Length-Controlled PEGylated Monocrystalline Superparamagnetic Iron Oxide Nanocomposite for MRI Contrast Agent
por: Deng, Li-Hua, et al.
Publicado: (2021)

Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool
por: Uchiyama, Mayara Klimuk, et al.
Publicado: (2015)

Preparation and characterization of peptide modified ultrasmall superparamagnetic iron oxides used as tumor targeting MRI contrast agent
por: Yin, Jie, et al.
Publicado: (2019)

Bisphosphonate-Anchored PEGylation and Radiolabeling of Superparamagnetic Iron Oxide: Long-Circulating Nanoparticles for in Vivo Multimodal (T1 MRI-SPECT) Imaging
por: Sandiford, Lydia, et al.
Publicado: (2012)

Long-term use of bisphosphonates in osteoporosis
por: Sadat-Ali, Mir, et al.
Publicado: (2017)

A reappraisal of generic bisphosphonates in osteoporosis
por: Kanis, J. A., et al.
Publicado: (2011)

Intravenous bisphosphonates for postmenopausal osteoporosis
por: Mottaghi, Peyman
Publicado: (2010)

Bisphosphonates adherence for treatment of osteoporosis
por: Vieira, Helena Parente, et al.
Publicado: (2013)

Hybrid Au@alendronate nanoparticles as dual chemo-photothermal agent for combined cancer treatment
por: Plan Sangnier, Anouchka, et al.
Publicado: (2018)

T(1)–T(2) Dual-modal MRI contrast agents based on superparamagnetic iron oxide nanoparticles with surface attached gadolinium complexes
por: Szpak, Agnieszka, et al.
Publicado: (2014)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

Long-term use of bisphosphonates in osteoporosis
por: Alwahhabi, Basmah K., et al.
Publicado: (2017)

Large T(1) contrast enhancement using superparamagnetic nanoparticles in ultra-low field MRI
por: Yin, Xiaolu, et al.
Publicado: (2018)

Development of Superparamagnetic Nanoparticles Coated with Polyacrylic Acid and Aluminum Hydroxide as an Efficient Contrast Agent for Multimodal Imaging
por: González-Gómez, Manuel Antonio, et al.
Publicado: (2019)

Differences between the bisphosphonates for the prevention and treatment of osteoporosis
por: Grey, Andrew, et al.
Publicado: (2006)

Osteoporosis and Bisphosphonate-Related Osteonecrosis of the Jaw Bone
por: Villa, Alessandro, et al.
Publicado: (2011)

Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
por: Reginster, Jean-Yves, et al.
Publicado: (2006)

Physicians’ perspectives on the treatment of osteoporosis patients with bisphosphonates
por: Gu, Tao, et al.
Publicado: (2016)

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2022)

ERT, HRT, Raloxifine, Calcitonin, or Bisphosphonates for Osteoporosis
por: Curtiss, Frederic R.
Publicado: (2003)

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk
por: Newcomb, P A, et al.
Publicado: (2010)

Author Correction: Large T(1) contrast enhancement using superparamagnetic nanoparticles in ultra-low field MRI
por: Yin, Xiaolu, et al.
Publicado: (2018)

The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Monoclonal antibody A7-superparamagnetic iron oxide as contrast agent of MR imaging of rectal carcinoma
por: Toma, A, et al.
Publicado: (2005)

Superparamagnetic iron oxide-C595: Potential MR imaging contrast agents for ovarian cancer detection
por: Shahbazi-Gahrouei, Daryoush, et al.
Publicado: (2013)

Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer
por: Mbese, Zintle, et al.
Publicado: (2021)

Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis
por: Pazianas, Michael, et al.
Publicado: (2010)

Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis
por: Cotté, F.-E., et al.
Publicado: (2009)

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis
por: Fuggle, Nicholas, et al.
Publicado: (2023)

Contrast agents for hepatic MRI
por: Morana, Giovanni, et al.
Publicado: (2007)

MRI Contrast Agents in Glycobiology
por: Geraldes, Carlos F. G. C., et al.
Publicado: (2022)

PEGylation of Superparamagnetic Iron Oxide Nanoparticles with Self-Organizing Polyacrylate-PEG Brushes for Contrast Enhancement in MRI Diagnosis
por: Illés, Erzsébet, et al.
Publicado: (2018)

Correction to: The therapeutic effect to eldecalcitol + bisphosphonate is superior to bisphosphonate alone in the treatment of osteoporosis: a meta-analysis
por: Zheng, Zaoqian, et al.
Publicado: (2020)

Ultra-small superparamagnetic iron oxide contrast agents for lymph node staging of high-risk prostate cancer
por: Czarniecki, Marcin, et al.
Publicado: (2018)

Erratum: Superparamagnetic Iron Oxide-C595: Potential MR Imaging Contrast Agents for Ovarian Cancer Detection
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mocbpd55l4bi81t3tldroe99ia